SCI, London, UK
Monday 5 and Tuesday 6 December 2016
Organised by SCI's Fine Chemicals Group
Register your interest in attending this event by emailing conferences@soci.org with the subject line 'PPI 2016 – Register my interest'.
Synopsis
Multiple vital cellular processes are regulated by specific interactions between proteins and examples of pathways mediated by protein-protein interactions (PPIs) include gene expression, proliferation, intracellular communication and apoptosis. Numerous diseases occur because pathways involving particular PPIs malfunction. The challenge is to understand the process by which one protein recognises another and binds to modulate its function. The rewards for a better understanding of particular PPIs include the potential to develop new molecular therapeutics and to develop probes to investigate systems biology. To date, only a few PPIs have been the subject of a drug discovery initiative.
Owing to the many opportunities presented by modulation of PPIs, this field has gained increasing scientific interest over the past decade and has seen many innovations from both academic and industrial research groups. This meeting aims to address recent advances in the characterisation and identification of new PPI inhibitors. Topics will include in silico assessment of PPI druggability, assay screening technologies for PPIs, structural biology approaches and fragment based drug design.
Attendees
This event is aimed at all scientists (students, post-docs, academics, industrialists) engaged in research projects on protein-protein interactions or additionally for those scientists interested in finding our more about research on PPIs. The range of topics covered in the meeting will hold appeal to chemists and biologists alike as in addition to covering fundamental elements of PPI research the meeting will be of interest to the drug discovery community eager to understand how the challenges of tackling protein-protein interactions to identify new drugs is being approached and executed across the pharmaceutical industry.
Monday 5 and Tuesday 6 December 2016
Organised by SCI's Fine Chemicals Group
Register your interest in attending this event by emailing conferences@soci.org with the subject line 'PPI 2016 – Register my interest'.
Synopsis
Multiple vital cellular processes are regulated by specific interactions between proteins and examples of pathways mediated by protein-protein interactions (PPIs) include gene expression, proliferation, intracellular communication and apoptosis. Numerous diseases occur because pathways involving particular PPIs malfunction. The challenge is to understand the process by which one protein recognises another and binds to modulate its function. The rewards for a better understanding of particular PPIs include the potential to develop new molecular therapeutics and to develop probes to investigate systems biology. To date, only a few PPIs have been the subject of a drug discovery initiative.
Owing to the many opportunities presented by modulation of PPIs, this field has gained increasing scientific interest over the past decade and has seen many innovations from both academic and industrial research groups. This meeting aims to address recent advances in the characterisation and identification of new PPI inhibitors. Topics will include in silico assessment of PPI druggability, assay screening technologies for PPIs, structural biology approaches and fragment based drug design.
Attendees
This event is aimed at all scientists (students, post-docs, academics, industrialists) engaged in research projects on protein-protein interactions or additionally for those scientists interested in finding our more about research on PPIs. The range of topics covered in the meeting will hold appeal to chemists and biologists alike as in addition to covering fundamental elements of PPI research the meeting will be of interest to the drug discovery community eager to understand how the challenges of tackling protein-protein interactions to identify new drugs is being approached and executed across the pharmaceutical industry.
